Oropharyngeal sanitization with electrolyzed superoxidation solution with neutral pH to prevent COVID-19

Evaluation of the potential in disinfecting or sanitizing the nose and mouth with an electrolyzed superoxidation solution with a neutral pH, as a treatment to reduce or avoid the spread of COVID-19 in health personnel at Hospital Enrique Cabrera during a period of four weeks. (COVID-19) - PreveCOVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000357

Enrollment

170

Registered

2021-03-16

Start date

2020-09-24

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19 SARS-CoV2

Interventions

Experimental group: Additional to the corresponding protective equipment, they will perform intranasal and oral disinfection with 0.0015%, Neutral Electrolyzed Water (SES). Intranasal disinfection con

Oral disinfection will be with mouthwashes that will be performed 3 times a day, with 10 mL of SES, for 60 seconds each. Both procedures will be performed during 4 weeks, which is the study follow-up

Saline Solution

Administration, Oral

Administration, Intranasal

electrolyzed superoxidation solution, mouthwashes

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Volunteer health professionals, over 18 years of age and belonging to the first line of care for COVID-19 patients. 2. Health professionals belonging to the Dr. Enrique Cabrera Cosio Hospital. 3. Negative diagnosis for SARS-CoV-2 by PCR. 4. Sign informed consent in writing of the volunteer.

Exclusion criteria

Exclusion criteria: 1. Over 70 years of age. 2. Positive diagnosis for SARS-CoV-2 by PCR. 3. Presence of symptoms compatible with COVID-19. 4. Other pathologies at the discretion of the researcher.

Design outcomes

Primary

Measure	Time frame
Absence of symptoms associated with COVID-19 in health professionals on the first line of care of COVID-19 patients (Yes, No). Measurement time: At baseline and, daily over the course of 4 weeks.	—

Secondary

Measure	Time frame
Adverse effects (oropharyngeal irritation, intolerance to application). Measurement time: At baseline and, throughout the course of the study (four weeks)	—

Countries

Mexico

Contacts

Public ContactRafael Gutierrez-Garcia

General Hospital Dr. Enrique Cabrera Cosio, Mexico

prosemed@yahoo.com.mx

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 25, 2026